Introduction
============

Cancer is one of the world\'s most devastating diseases to the human population. Surgery, chemotherapy, and radiotherapy (RT) are the leading cancer treatment approaches in the clinical field, addressing the needs of almost all cancer patients [@B1]. Although X-rays can fatally damage tumor cells, they also have a high toxicity to normal tissue [@B2]. Hence, it is very important to strike a balance between inhibiting tumor growth and reducing side effects to normal tissue by controlling the dose of radiation administered to patients.

With the development of nanotechnology and nanomedicine, new strategies for cancer management have been developed. Photodynamic therapy (PDT) has been extensively applied as a less invasive, low toxicity, and highly selective therapeutic modality for clinical cancer treatment [@B3]. Typically, in the presence of oxygen, photosensitizers are activated by light, of an appropriate wavelength, to produce cytotoxic reactive oxygen species (ROS) [@B3]. Compared with chemotherapy and RT, PDT has an intrinsic safety and has fewer side effects to normal tissue. Breakthroughs in light-based diagnostic and therapeutic interventions have ushered in a new frontier in biomedical research. However, visible light suffers from poor transmission through tissues due to reflection, scattering, and absorption. The rapid decay in the intensity of the excitation light source as the light travels through tissues reduces the efficiency of tumor destruction when the tumors are in deep tissue. Achieving effective treatment of deep-seated tumors is still a major challenge for light-based diagnostics and therapeutics.

As an ionizing radiation with photon energies of kiloelectronvolts (keV) to megaelectronvolts (MeV) and excellent tissue penetration depth, RT is the leading cancer treatment approach, which addresses the needs of more than 70% of cancer patients. Ionizing radiation can induce DNA damage in cancer cells, resulting in highly efficient cancer cell destruction [@B4]. However, to efficiently destroy cancer cells and inhibit tumor growth, a high dose of X-rays (50-80 Gy) is generally needed, especially for the treatment of deep-seated tumors, increasing the toxicity of radiation on the healthy tissue that lies close to the target tissue.

Researchers have thus hypothesized the use of PDT with X-rays, instead of laser light, and haematoporphyrin derivatives (HPD) to extend the possibilities of PDT [@B5]. With the high tissue-penetrability of X-rays, researchers proposed X-ray induced photodynamic therapy (X-PDT) for improved therapeutic outcomes and reduced radiation damage to normal tissue for the treatment of deep-seated cancer. The principle of X-PDT is to use an energy transducer to transfer X-rays to optical luminescence and initiate the RT and PDT processes [@B6]-[@B9]. Since the concept of nanoparticle-mediated X-PDT was proposed in 2006 [@B10], X-PDT has undergone more than a decade of development *in vitro* and *in vivo* (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}), and several reviews focusing on the development of nanosensitizers have been published and references cited therein [@B11]-[@B13]. A recent review has systematically described the interaction mechanisms between X-rays and X-ray-sensitive materials [@B14]. Herein, this tutorial review aims to provide an overview of X-PDT, including the concept, the design considerations of nanosensitizers for X-PDT, the modelling of energy deposition in nanosensitizers, a possible cell-death mechanism initiated by X-PDT, and the prospects for future development. We attempt to summarize the main developments that have occurred over the past decades. Finally, possibilities and challenges for the clinical translation of X-PDT are also discussed.

Principle of X-PDT
==================

X-PDT process
-------------

The energy of X-rays used in clinical RT is in the range of hundreds of keV to MeV. As a result, most traditional photosensitizers used for cancer PDT cannot be effectively activated by X-rays. In this regard, a physical transducer is required to absorb the X-ray irradiation energy and transfer it to photosensitizers to produce the cytotoxic singlet oxygen (^1^O~2~) necessary for tumor destruction. In the classical X-PDT model, this energy transfer is achieved by converting the absorbed x-ray energy it into optical photons of the appropriate wavelength that can be absorbed effectively by photosensitizers. These transducers are generally called scintillators and exhibit X-ray excited optical luminescence (XEOL). In addition, there are other possible mechanisms of energy transfer between X-ray absorbers and photosensitizers. For instance, acridine orange is a powerful photosensitizer, that has been shown in cancer models and sarcoma patients to be effective under low-dose X-ray irradiation, without use of a specific scintillator transducer [@B15].

As illustrated in Figure [2](#F2){ref-type="fig"}, the classical X-PDT process can be divided into three main parts: (1) The nanoscintillators are irradiated by X-rays to generate XEOL. (2) The generated XEOL is absorbed by nearby, well-matched photosensitizers to produce ^1^O~2~, which can directly damage the cell membrane phospholipids of tumors while, at the same time, the absorbed ionizing radiation can generate radical species and break DNA double-strands. (3) The generated ROS induce cancer cell death by a combination of the PDT and RT processes to achieve effective cancer treatment. In this way, based on the effective energy transfer in the photosensitizer-loaded nanoscintillators (termed as nanosensitizers), X-rays can be used as the excitation light source to trigger PDT for the treatment of deep-seated tumors.

On account of the distinctive routes to cell death, each part in X-PDT suppresses the cell repair mechanism of the other, leading to enhanced treatment outcomes. As shown in Figure [3](#F3){ref-type="fig"} [@B16], compared with RT (0-5 Gy), X-PDT induced significant cell death and reduced clonogenicity at all doses. An apoptotic/necrotic assay (Figure [3](#F3){ref-type="fig"}A) indicated that cells treated with RT showed a modest level of apoptosis and no detectable necrosis at 24 h, while cells treated with X-PDT manifested extensive cell necrosis. These results demonstrated that a membrane-targeted PDT process could cause oxidative degradation of unsaturated lipids and surface proteins. A lipid peroxidation assay confirmed that both X-PDT and RT showed significant lipid oxidation, while X-PDT showed a 1.5-fold higher level of lipid peroxidation than that of RT only (Figure [3](#F3){ref-type="fig"}B). Also, the clear, comet-like appearance of cells and loosened nuclei indicated that both X-PDT and RT induced noticeable DNA damage (Figure [3](#F3){ref-type="fig"}C). A western blot assay further confirmed the impacts. As shown in Figure [3](#F3){ref-type="fig"}D, the levels of COX-2 (cyclooxygenase-2) and γ-H2AX (phosphorylated histone H2AX) both increased after the X-PDT treatment, caused by membrane oxidation and breakage of the DNA double-strand, respectively. These findings suggest that X-PDT combines the processes of RT and PDT. Recent studies further confirmed this mechanism for X-PDT [@B7], [@B17].

Experiments at the cellular level demonstrated that X-PDT is not only a PDT derivative, but also a type of RT derivative. PDT can excite photosensitizers to generate ^1^O~2~. RT can rapidly induce water radiolysis to produce hydroxyl radicals (•OH). The combination of RT and PDT, *i.e.* X-PDT, can produce a large amount of ROS, which plays an important role in causing damage to the cell membrane and DNA [@B18]. The X-PDT strategy affords several benefits over conventional RT. First, X-PDT can kill cells that are resistant to RT alone (*e.g.*, glioblastoma cells, prostate cancer cells, and colorectal cancer cells). The PDT induced cell membrane damage, together with the radiation caused DNA damage, synchronously induce tumor cell apoptosis and necrosis. Second, the low irradiation dose (typical total dosage: \<5 Gy) used in X-PDT is much lower than that of traditional clinical RT (typical total dosage: 60-80 Gy). Thus, X-PDT would have less side effects on normal tissue. Third, the X-PDT process can be activated with a single dose, at a lower dose rate compared with traditional RT. It is known that irradiation induced toxicity is positively correlated with the dose rate. In X-PDT, a typical irradiation dose necessary for treatment is in the range of 2-5 Gy, which is often comparable to one portion of the total dose used in conventional RT (*e.g.* 50-80 Gy in 2-Gy quantities).

Design considerations of X-PDT
------------------------------

Despite the potential advantages of X-PDT over PDT, some crucial criteria need to be addressed before biomedical applications of the X-PDT strategy are possible. These criteria may enable more effective tumor ablation through the use of a nanosensitizer-mediated PDT process with low-dose X-rays.

Since the initial proof-of-principle study of X-PDT, several theoretical models have been generated to guide the development of nanosensitizers and estimate the efficacy of X-PDT. The initial simulations put forth by Morgan and coworkers, however, were not encouraging [@B19]. Morgan *et al.* estimated the X-ray energy and dose required to produce a lethal dose of ^1^O~2~ in tissue, depending on the radiation dose absorption efficiency of the nanoscintillators and the ^1^O~2~ generation after absorption of X rays (per MeV). Therefore, based on the reported lethal dose of ^1^O~2~, the authors gave a practical relationship between the necessary emission yield of nanoscintillators (photons·MeV^-1^) and the incident X-ray energy for estimating the feasibility of new, candidate nanoscintillator-photosensitizer conjugates for use in X-PDT. Based on the assumption that X-ray photons which hit a nanoparticle would transfer all of their energy to that nanoparticle, the study concluded that the strategy would be effective for photon sources at intensities \<300 kV due to enhanced X-ray absorption near the K-edge of the nanoparticle material [@B20]. However, many uncertainties existed in the simulation, including large variations in the reported values for cellular uptake and the singlet oxygen lethal dose, wildly optimistic assumptions, and oversight of physical radiosensitization effects associated with the presence in cells of high-Z X-PDT nanoscintillators. If and how the time scale for delivery of singlet oxygen affects the dose required for cell death were not addressed. Additionally, Morgan only showed the simulated results using LaF~3~ nanoparticles, which have a low light yield under X-ray irradiation (Figure [4](#F4){ref-type="fig"}A). Overall, this simulation was a first attempt and raised valid questions about the practicality of X-PDT as an effective treatment option. Figure [4](#F4){ref-type="fig"}A shows the light yield limits for several commonly used scintillators in X-ray imaging screens and films for projection imaging, fluoroscopy, and computed tomography (CT) [@B21]. As indicated, the fundamental limit is the smallest for fluorides, which have the largest band gap, and the largest for sulfides, which have the smallest band gaps.

Bulin *et al.* found that Morgan\'s simulation was restrictive and overestimated the energy deposition in nanoscintillators [@B22]. An alternative model for nanoscintillator-mediated PDT was proposed to better simulate of the efficiency of X-PDT using a GEANT4-based Monte Carlo program [@B22]. This model takes into account that secondary electrons generated in the nanoscintillator have ranges much greater than the size of the nanoscintillator and thus most of the X-ray energy is transferred to the medium outside the nanoscintillator. The conditions in Bulin\'s simulation were restricted to 10 nm diameter nanoparticles distributed in a tumor with a high occupancy ratio, and the spatial energy distribution that resulted from the interaction between the X-ray photons and the nanosensitizers was estimated. In this simulation, a new loss parameter η~nano~, which corresponds to the fraction of total energy that is deposited in the scintillators in the mixed media, was introduced. Using this parameter, the study finds that, most of the X-ray energy is absorbed by water molecules and does not contribute to scintillation. The process of excitation of nanoscintillators by X-rays can therefore be broken down into two phases. In the first phase, X-ray photons are absorbed by the medium and transfer their energy to electrons. Due to its higher abundance, water is the primary absorber of X-ray radiation. In the second phase, these energetic electrons propagate through the tissue and deposit energy along their path through inelastic scattering. When an electron passes through a nanoparticle, some of its energy can be transferred to stimulate the emission of scintillation photons. The amount of energy transferred is a function of the electron\'s energy, the nanoparticle size and its material composition (electron stopping power and density). This indirect transfer of energy is the primary mechanism for X-ray luminescence of nanoscintillator suspensions. Considering the linear energy transfer of electrons, the typical energy transfer between an electron and a nanoparticle with a diameter of 20 nm is on the order of 10 eV. Based on the simulation, the calculations for various nanomaterials under 100 and 500 keV irradiations are listed in Figure [4](#F4){ref-type="fig"}B. As indicated, gold has the largest absorption capacity for X-ray photons (Abs.) of all the materials listed and its use results in the highest energy deposition in matter (E~matter~) [@B23]. However, only a small percentage of the energy deposition is transferred to nanoparticle, as quantified by the loss parameter η~nano~.

As previously discussed, at physiological nanoparticle concentrations (i.e. \<1 mg·ml^-1^), the absorption of energy by nanoparticles is mainly driven by inelastic electron scattering and is nearly independent of the nanoparticle X-ray stopping power. Following this, Klein et al proposed a simplified model based on electron cross sections to describe this process [@B24]. The X-ray luminescence yield is a function of the radiation dose to the tissue (Gy=J·kg^-1^), the nanoparticle mass concentration *C~NP~* (g·cm^-3^), the light yield of scintillator (*Y~sc~*), and the electron cross-sections (*μ/ρ*) of the tissue and the nanoparticle material. Using this framework, the density of photons emitted by a dilute suspension of scintillators (*N~scint~*) can be computed according to:

\(1\)

(where *μ/ρ* can be obtained from the ESTAR database of the National Institute of Standards and Technologies (NIST)).

The model further assumed that all photons were converted to singlet oxygen, and cells are spherical structures with a diameter of 10 μm. Accordingly, the number of singlet oxygen per cell (*N*~1O2~) was calculated as:

\(2\)

Compared to to the X-ray cross-section, the electron absorption cross-section is a better predictor of the efficacy of X-PDT, at least within the correct order of magnitude, as indicated by the sample photon yields that were computed. In fact, it has been shown that the model provides an upper bound for the actual number of scintillation photons emitted. Using the same assumption and LaF~3~ as the sample, the electron cross-section model predicts \~10^6\ 1^O~2~ molecules per cell over a wide energy range of excitation energies, which is below the required 10^7\ 1^O~2~ per cell PDT threshold for cell killing. It should be noted that this model does not account for the microscopic inhomogeneity in radiation dose that results from the high density of nanoparticles compared to water. This local increase in dose and ROS production around dense nanoparticles is being investigated as a potential approach for increasing the efficacy of cancer radiotherapy. Most nanoscintillators are made of dense materials, and therefore they also result in local radiosensitization independently of PDT. For greater accuracy, Monte Carlo simulations, which model photon-nanoscintillator interactions in greater detail, are necessary.

Taken as a whole, the classical model of X-PDT is unable to fully explain the efficacy of X-PDT regimens seen during pre-clinical tests. The luminescence of nanoscintillator suspensions excited by X-ray is several orders of magnitude lower than the optical photon dose required for conventional PDT. The efficacy of X-PDT may therefore be due to synergistic effects between RT and PDT [@B25]. The X-PDT process may also involve non-optical forms of energy transfer between nanoparticles and covalently bound photosensitizers, such as Förster resonance energy transfer (FRET) and low-energy Auger electrons. Last, an often-ignored side-effect of X-PDT is that the presence of high-Z nanoparticles within cells enhances radiation dose within nanometers of their surface [@B26]. This effect can increase cell killing regardless of PDT, thus suitable controls must be employed when testing X-PDT agents. Nanoparticles can also catalyze the radiation-induced formation of radicals and ROS, further enhancing cell killing [@B27]. Thus, further work remains to be done to fully elucidate the chain of physicochemical events that enables X-ray radiation to activate photosensitizers.

The results derived from these simulations provide important guidelines for the design of nanosensitizers and for quantifying ^1^O~2~ generation in the frame of therapy which combines RT and the PDT effects. However, many factors, especially scintillation light yield, biodistribution after injection, photosensitizers, efficiency of transfer toward photosensitizers, and efficiency of irradiation absorption of radiosensitizers, will affect the efficiency of X-PDT. As shown in Figure [5](#F5){ref-type="fig"}, the commonly considered characteristics of scintillators and photosensitizers when designing nanosensitizers for X-PDT are listed. First, to effectively trigger PDT under X-ray irradiation, the scintillators should have a strong absorption capacity for irradiation, and strong X-ray-excited optical luminescence (\>15 photons·keV^-1^). Figure [4](#F4){ref-type="fig"}A reveals the light yields of several of the most commonly used scintillators, which showed that the light yield for an ideally activated scintillator would have a maximum energy efficiency of close to 40% [@B21]. Although there may be a limitation on the light yield, a recent study designed a new class of scintillators, which had strong X-ray absorption and XEOL [@B28]. There, the Huang group prepared all-inorganic perovskite scintillators with size of 9.6 nm using a wet chemical synthesis approach. Compared with conventional bulk scintillators (CsI:Tl, PbWO~4~, YAlO~3~:Ce, and Bi~4~Ge~3~O~12~), the perovskite scintillators converted small doses of X-ray photons into multi-colored visible light. Furthermore, to achieve biomedical applications, the as-prepared scintillators are required to have good biocompatibility, such as low-toxicity, weak cellular immune response, minimal protein adsorption and cell adhesion, long blood circulation, and great capabilities for escaping the reticuloendothelial system. Besides, the scintillators of a suitable size generally benefited from passive tumor accumulation mediated by the enhanced permeability and retention (EPR) effect. It is important to note, however, that when the EPR effect was first discovered, it was extolled by many as a magic weapon against cancer; it is clear now that this is not the case. Delivering nanoparticles to cancer cells is an extremely complicated process. One of the major challenges in the field of tumor-targeting delivery is that the EPR effect is much more pronounced and uniform in xenograft models than it is in most human cancers. Reviews on this and other key problems have been carefully listed and discussed at length [@B29], [@B30]. Second, photosensitizers should have excellent irradiation stability, high ^1^O~2~ quantum yield in aqueous solutions, and good biocompatibility. Third, to achieve highly efficient energy transfer from scintillators to photosensitizers, the absorption of the photosensitizers should have maximum overlap with the XEOL of the scintillators. Also, an appropriate distance between scintillators and photosensitizers is required for effective energy transfer. Last but not least, for *in vitro*/*in vivo* applications of X-PDT, the as-prepared scintillators should be modified with a proper surface coating and conjugated with tumor targeting ligands. Such modifications enable nanosensitizers to have good performance in biological systems, such as improved pharmacokinetics, high selectivity to cancer cells, preferential accumulation in tumor tissue, and rapid clearance from normal tissue [@B31]. In all, these optimization strategies will give rise to efficient tumor accumulation and destruction, and reduce damage to normal tissues as well. Researchers in this area have made great efforts to balance the properties of scintillators and photosensitizers. In the next section, we will introduce the typical scintillators and matched photosensitizers to evaluate X-PDT efficacy. These scintillators include fluorides, oxides, micelles, high-Z organometallic complexes, phosphors, metal-organic complex containing heavy metal clusters, and luminescent organic bridging ligands.

Current development of classic X-PDT
====================================

As described above, the concept of nanoparticle-mediated X-PDT was first proposed in 2006 [@B10]. Since then, there have been many attempts to advance the development of X-PDT. Figure [1](#F1){ref-type="fig"} presents a timeline of representative milestones in X-PDT technology. Table [1](#T1){ref-type="table"} gives a more detailed summary of these findings, which can be separated into three developmental stages. During the initial period, research demonstrated that X-PDT can generate ^1^O~2~ in solution using fluorides and oxides as the transducers at the same dosages used for RT (*i.e.* 6-8 Gy). Then, the investigations focused on *in vitro* demonstrations under a selected dosage for RT. There was no demonstration of this technology *in vivo* using a low-dosage of X-rays until 2015. Progress in the design and modification of nanosensitizers has led to more comprehensive studies. In the following section, we will give examples and discuss the classic X-PDT scheme based on the time lines in Figure [1](#F1){ref-type="fig"}.

Early investigations of X-PDT in solution
-----------------------------------------

In the early stages, most of the investigations demonstrated the feasibility of ^1^O~2~ generation by employing fluorides and oxides of scintillators as transducers. As one of the mostly studied scintillators, rare-earth-element doped nanomaterials can absorb incoming high energy radiations and transfer them to luminescent centers, resulting in efficient luminescence in the visible light region [@B32]. Porphyrin is a photosensitizer that is commonly applied in clinical PDT, and Tb^3+^ exhibits efficient green luminescence that matches well with the absorption band of porphyrin. In 2008, the Chen group synthesized meso-tetra(4-carboxyphenyl) porphine (MTCP) conjugated LaF~3~:Tb nanoparticles (LaF~3~:Tb-MTCP) to investigate ^1^O~2~ generation following the X-PDT process [@B33]. The nanoparticles were about 10-15 nm in size, which emitted green XEOL centered at 540 nm. Under X-ray irradiation (0.44 Gy·min^-1^, 13.2 Gy), the luminescence of 9,10-anthracenedipropionic acid (ADPA) was quenched by both MTCP and LaF~3~:Tb-MTCP, with the quenching by the latter more than doubled (Figure [6](#F6){ref-type="fig"}A). In another study, the Yang group demonstrated X-PDT effects using mesoporous LaF~3~:Tb nanoparticles (Figure [6](#F6){ref-type="fig"}B) [@B34]. Under X-ray irradiation, the green XEOL of LaF~3~:Tb could be absorbed by an adsorbed rose bengal (RB) (Figure [6](#F6){ref-type="fig"}B). Under X-ray irradiation, RB alone could quench about 40% of the fluorescence of 1,3-Diphenylisobenzofuran (DPBF), while the quenching induced by RB-adsorbed LaF~3~:Tb was about two-fold higher than that of RB alone (Figure [6](#F6){ref-type="fig"}C). Then, the same group coated a layer of silica on the mesoporous LaF~3~:Tb scintillators [@B35]. After integration with RB, the nanosensitizers showed an efficient generation of ^1^O~2~ under X-ray irradiation. Besides fluorides, oxides were also employed to investigate the efficacy of X-PDT. The Dujardin group conjugated silica coated Tb~2~O~3~ (Tb~2~O~3~\@SiO~2~) core-shell nanoparticles with porphyrin (Figure [6](#F6){ref-type="fig"}D) [@B36]. The XEOL matched well with the absorption of porphyrin (Figure [6](#F6){ref-type="fig"}E), and ^1^O~2~ was generated under X-ray irradiation (5.4 mGy·s^-1^), as indicated by an increase in the emission of 3-p-(amino phenyl) fluorescein (APF) (Figure [6](#F6){ref-type="fig"}F).

Other lanthanide-based structures were also investigated. For example, the Réfrégiers group reported a hydrophilic micelle for X-PDT [@B37]. The micelles consisted of lanthanide chelates GdEuC1~2~ and hypericin (Hyp) as photosensitizers that were incorporated into their hydrophobic regions (Figure [7](#F7){ref-type="fig"}A). Upon X-ray irradiation, the GdEuC1~2~ micelles showed characteristic luminescence of Eu^3+^ in the visible spectral region, which matched well with the absorption of Hyp (Figure [7](#F7){ref-type="fig"}B). The ^1^O~2~ production was illustrated by an abundance of 1-pyrenecarboxaldehyde, which was measured by mass spectrometry (Figure [7](#F7){ref-type="fig"}C). As a high-Z organometallic complex, \[M~6~Li~8~La~6~\]~n~ (M = Mo, W, Re) clusters were reported to be exclusively quenched by molecular oxygen to form ^1^O~2~ [@B38]. Octahedral molybdenum (n-Bu~4~N)~2~\[Mo~6~I~8~(OOC-1-adamantane)~6~\] clusters were embedded in polystyrene films to form an aggregate and enhance radioluminescence (Figure [7](#F7){ref-type="fig"}D) [@B39]. Obvious characteristic emission at 1274 nm was observed, indicating ^1^O~2~ generation. Based on these results, the mechanism of cluster-mediated X-PDT was proposed (Figure [7](#F7){ref-type="fig"}E). Following the concept of nanoparticle-mediated X-PDT, these attempts made in the early stages have propelled the development of feasible methods for the design of nanosensitizers and their applications in cancer management.

X-PDT for killing cancer cells
------------------------------

The above studies have demonstrated the ability of the X-PDT strategy to produce ROS in solution. This strategy was then applied to killing cancer cells, where the effective cellular uptake should first be considered in order to generate cytotoxic ROS intracellularly.

Following the concept of X-PDT, the Misawa group analyzed a number of radiosensitizers for X-PDT *in vitro* [@B40]. The radiosensitizers, including TiO~2~, ZnS:Ag, CeF~3~, and quantum dots (CdTe and CdSe), in particulate form were designed to generate ROS inside or outside HeLa cells. Under high-doses of X-ray irradiation, a proportional increase of ROS generation was observed with increasing concentrations of TiO~2~, ZnS:Ag, CeF~3~, and CdSe quantum dots. Also, the survival fraction of the HeLa cells, obtained by a cell proliferation kit, showed the insignificant effects of the sensitizing materials, compared with the control group (*i.e.,* cells irradiated directly by X-ray). To enhance the sensitization effect, surface modification of the radiosensitizers was used to help internalize radiosensitizers into the HeLa cells and reduce the cell viability. However, the cell damage mechanism employed by these radiosensitizers was different from classical RT caused by double-strand breakage in DNA. Analysis of the cell damage mechanism by these radiosensitizers under X-ray irradiation needs further investigation.

The Tata group employed terbium doped gadolinium oxysulfide particles (Gd~2~O~2~S:Tb, 20 micron dimension) to activate Photofrin II (Photo II) through X-ray induced luminescence, and evaluated the efficacy of X-PDT on the human glioblastoma cell line [@B41]. Severe suppression in the cellular metabolic activity was observed under clinically relevant conditions (Photo II at 20 µg·mL^-1^) with Gd~2~O~2~S:Tb particles and X-rays (120 kVp) (Figure [8](#F8){ref-type="fig"}A). However, the micron-sized particles suffered from the poor circulation features in a living body, hampering the *in vivo* applications. To minimize the issues from size, the Vo-Dinh group functionalized commercial yttrium oxide (Y~2~O~3~) scintillators (\~12 nm diameter) with a psoralen (Ps)-containing, thiol-modified fragment of the HIV-1 TAT peptide and evaluated the efficacy of *in vitro* therapy using X-PDT (Figure [8](#F8){ref-type="fig"}B,C) [@B42].

Persistent luminescence (also called afterglow) phosphors can emit luminescence long after excitation, and have been used as nanoprobes in small animal optical imaging without the autofluorescence background interference [@B43]. Persistent luminescence allows the host to store the excitation energy, and then slowly release the energy from the trapped charge carriers to emit a long-lasting phosphorescence. This unique property can be used as a potential energy mediator for PDT treatment [@B44]. The Chen group first employed ZnS:Cu,Co afterglow nanoparticles to investigate the efficacy of X-PDT *in vitro* [@B45]. As first generation persistent luminescence materials, ZnS:Cu emits green luminescence, which overlaps well with the absorption of tetrabromorhodamine-123 (TBrRh123) (Figure [8](#F8){ref-type="fig"}D). Furthermore, the XEOL afterglow of ZnS:Cu,Co can last for more than 10 min after X-ray irradiation is ended (Figure [8](#F8){ref-type="fig"}E). The nanosensitizers were efficiently ingested by the cancer cells, inducing a sharp decrease of cell viability under X-ray irradiation (2 Gy). However, the applied X-ray irradiation alone had a negligible effect on the destruction of the cancer cells (Figure [8](#F8){ref-type="fig"}F). This study made afterglow nanoparticles a potential candidate as a light source for activating PDT for deep-seated tumors.

Besides transitional optical phosphors, other materials were also evaluated as nanosensitizers to achieve X-PDT. The Salviati group irradiated porphyrin conjugated SiC/SiOx nanowires using a clinical RT instrument with a relatively low X-ray irradiation dose (2 Gy, 6 MeV) (Figure [8](#F8){ref-type="fig"}G) [@B46]. The cell population was reduced by about 75%, with respect to control cells, as evidenced from the clonogenic survival assay (Figure [8](#F8){ref-type="fig"}H). Further experiments showed a remarkable reduction of intracellular adenosine triphosphate (ATP), which is directly correlated with cell viability (Figure [8](#F8){ref-type="fig"}I). However, the mechanism of ^1^O~2~ generation in this research was unclear, as there was no evidence showing that the nanowires could emit XEOL under X-ray irradiation.

As investigated by the above evaluations in solution and at cellular levels, these results have proven that under X-ray irradiation, transducers can transfer irradiated energy to bound photosensitizers to generate ROS and induce cell death. Although some cases do not exactly follow the mechanistic cell death of X-PDT, we still can learn from these studies and gather some strategies for *in vivo* applications.

*In vivo* X-PDT for cancer treatment
------------------------------------

In the first 10 years of development, there were virtually no X-PDT studies performed *in vivo*. The proposer of the concept of X-PDT commented in 2014 that "previous attempts using X-rays to activate photosensitizers were not very successful, since the traditional PDT photosensitizers could not be efficiently activated by X-rays" [@B47]. To bring X-PDT technology forward, it is critical to demonstrate that nanosensitizers can be excited by external X-ray irradiation to generate XEOL and activate X-PDT *in vivo*. In this section, we will summarize the progress of transforming the X-PDT concept into more realistic *in vivo* applications.

Besides commenting on previous investigations, the Chen group also exploited copper-cysteamine complex (Cu-Cy) microparticles (3-10 µm) and evaluated their X-PDT performance for *in vivo* cancer treatment [@B47]. An *in vitro* study on human breast cancer cells (MCF-7) showed significant cell death using Cu-Cy particles activated by X-rays, and *in vivo* treatment that was conducted on a subcutaneous tumor model inhibited tumor growth after an intratumoral injection of Cu-Cy particles and X-ray irradiation (5 Gy). These results demonstrated that Cu-Cy particles could be efficiently activated by X-rays to produce ROS for cancer treatment. Although the results were positive, the exact mechanism of ROS production was not clear, as there was no photosensitizer in the structure of Cu-Cy. A recent study demonstrated the Cu-Cy nanoparticles could regulate the tumor microenvironment for *in situ* glutathione (GSH)-activated and H~2~O~2~-reinforced chemodynamic therapy for drug-resistant breast cancer [@B48]. The Cu-Cy nanoparticles could generate toxic •OH *via* a Fenton-like reaction by reacting with local GSH and H~2~O~2~.

The efficacy of X-PDT *in vivo* was further demonstrated by others and us [@B8], [@B49]. The Shi and Bu group coated a semiconductor layer of ZnO on Ce-doped LiYF~4~ nanoparticles (LiYF~4~\@ZnO) and then investigated the *in vivo* efficacy of X-PDT with minimal oxygen dependence (Figure [9](#F9){ref-type="fig"}A) [@B49]. Ce-doped LiYF~4~ exhibited strong emission bands in the Ultraviolet (UV) region (305 and 325 nm) that matched the bandgap of the surface-bound ZnO layer. The subsequently formed excitons (the electron-hole (e^-^-h^+^) pairs) interacted with water and oxygen molecules to form free radicals (Figure [9](#F9){ref-type="fig"}B). These ROS were mainly produced through an oxygen-independent PDT (type I reaction) mechanism, and could cause irreversible oxidative damage to DNA, lipids, and proteins, even in the low oxygen environment. *In vitro* studies showed significant ROS production under X-ray irradiation (3 Gy), regardless of the oxygen tension, confirming the highly efficient X-PDT both in normoxic (21% O~2~) and hypoxic (2% O~2~) cells (Figure [9](#F9){ref-type="fig"}C). Furthermore, the *in vivo* study showed that the tumor growth was significant inhibited after intratumoral injection of LiYF~4~\@ZnO into subcutaneous tumors and irradiation with X-rays (8 Gy) (Figure [9](#F9){ref-type="fig"}D). Following this strategy, the Bu group further combined scintillators and heavy metals to absorb X-rays and transmit the energy to photosensitizers [@B17]. In this design, LiLuF~4~:Ce generated X-ray excited UV luminescence, which was absorbed by the photosensitizers (Ag~3~PO~4~) to generate •OH. To make full use of the UV luminescence produced by LiLuF~4~:Ce, a cisplatin prodrug Pt(IV) was utilized as a sacrificial electron acceptor to increase the yield of •OH by separating the electrons and holes in Ag~3~PO~4~. Additionally, cisplatin was produced upon the reduction of Pt(IV) and further enhanced the damage caused by •OH. Through a two-step amplification strategy, LiLuF~4~:Ce\@Ag~3~PO~4~\@Pt(IV) nanoparticles (LAPNP) enhanced the curative effects of X-PDT.

Our group developed an X-PDT strategy based on the type II PDT mechanism and achieved efficient, low-dose*in vivo* cancer treatment [@B8]. The nanosensitizers consisted of a core made of SrAl~2~O~4~:Eu (SAO) and a silica coating loaded with merocyanine 540 (MC540), as shown in Figure [10](#F10){ref-type="fig"}A. Under X-ray irradiation, SAO emitted bright green luminescence, which was well absorbed by the loaded photosensitizer, MC540 (Figure [10](#F10){ref-type="fig"}B). ^1^O~2~ was generated following a typical type II PDT mechanism. Compared to the low cytotoxicity of controls, the X-ray irradiation of radioresistant human glioblastoma (U87MG) cells pre-incubated with MC540-loaded mesoporous silica coated SAO (M-SAO\@SiO~2~) nanosensitizers showed a viability drop to 38% (Figure [10](#F10){ref-type="fig"}C). Furthermore, *in vivo* X-PDT studies demonstrated that subcutaneous U87MG tumor growth was almost completely inhibited after an intratumoral injection of the M-SAO\@SiO~2~ nanosensitizers, as compared with the controls (Figure [10](#F10){ref-type="fig"}D). In sum, *in vitro* and *in vivo* studies have shown that a low dose of X-rays (0.5 Gy, single dose) sufficiently damaged radioresistant cancer cells and caused tumors shrinkage, while leaving normal tissue unaffected. Moreover, unlike the previously studied scintillators, SAOs are highly hydrolytic and can be degraded into low-toxic ions and cleared from the host, causing no long-term side effects.

Heavy (high-Z) elements can enhance the absorption capacity of X-ray irradiation and have been used clinically for imaging [@B28], [@B50]. The enhancement is also helpful for both the PDT and RT steps of X-PDT, which have been demonstrated in recent studies of X-PDT by incorporating heavy atoms into nanosensitizers. For example, the Yang group doped W(VI) into ZnGa~2~O~4~:Cr (ZGO:Cr/W) and achieved ultralow-dose X-ray activation for cancer treatment (Figure [11](#F11){ref-type="fig"}A) [@B51]. As shown in Figure [11](#F11){ref-type="fig"}B, after doping with W(VI), the intensity of XEOL increased sharply compared with the nanoscintillators without W(VI). Interestingly, the X-rays excited afterglow luminescence could activate a long-term PDT process. *In vivo* experiments demonstrated that low-dose X-ray irradiation (0.18 Gy) was enough to activate the X-PDT process and cause significant delay of tumor growth (Figure [11](#F11){ref-type="fig"}C). These advances allow X-PDT to be activated by intermittent X-ray irradiation, which can further minimize ionizing-irradiation induced toxicity. Furthermore, the Li group prepared Gd~2~(WO~4~)~3~:Tb nanoparticles and demonstrated their potential for use in multifunctional theranostics for CT/MRI-guided X-PDT, which showed a higher tumor growth inhibition efficiency at a low X-ray dose (6 Gy) than that seen for RT alone [@B52].

Au has great radio-sensitization effect, owing to the strong interaction with ionizing radiation [@B53]. Osakada et al. found bovine serum albumin (BSA) protected Au clusters (Au-BSA) could generate XEOL with an emission peak at 667 nm under hard-X-rays [@B54]. Although these Au clusters only were excited by hard-X-rays [@B55], the preliminary results proposed the possibility of using biomoleculse (such as BSA) to mediate the activation of X-ray irradiation on metal clusters. Our group reported the aggregates (AIE-Au) of conjugations of glutathione-protected gold clusters (GCs) and rose bengal (RB) (Figure [12](#F12){ref-type="fig"}A) [@B56]. The AIE-GCs enhanced the X-ray-excited luminescence by 5.2-fold than that of single GCs (Figure [12](#F12){ref-type="fig"}B). X-ray irradiation could stimulate X-PDT effect in cells (Figure [12](#F12){ref-type="fig"}C). Meanwhile, an enhanced radiatherapy effect was also activated, due to the large amount of radiosensitive high-Z gold atoms in AIE-Au nanoparticles (Figure [12](#F12){ref-type="fig"}D). The combined therapy resulted in significantly reduced U87MG cells proliferation (Figure [12](#F12){ref-type="fig"}E). The experiments *in vivo* showed that AIE-Au could effectively suppress tumor growth by triggering the generation of reactive oxygen species (^1^O~2~ and •OH) under low-dose X-ray irradiation, and realize highly effective treatment of various irradiation-resistant tumors through the unique X-PDT mechanism (Figure [12](#F12){ref-type="fig"}F-H).

Moreover, Dou et al. prepared a radiation-responsive scintillating nanotheranostic system (NSC\@mSiO~2~-SNO/ICG) by loading S-nitrosothiol groups (SNO, a NO donor) and indocyanine green (ICG, a photosensitizer) on mesoporous silica-coated Eu^3+^-doped NaGdF~4~ scintillating nanocrystals (NSC) (Figure [13](#F13){ref-type="fig"}A) [@B57]. The energy transfered from NSC to ICG activated the X-PDT process to generate large amount of ROS. Meanwhile, the S-N bond in SNO was excited to produce high NO concentration in tumors under X-ray irradiation, which improves the tumor hypoxia due to the enhanced vasodilation. (Figure [13](#F13){ref-type="fig"}B).

As opposed to incorporating high-Z elements into the matrix of scintillators, bioconjugation of clinical photosensitizers containing high-Z elements would be a better choice to increase the cell cytotoxicity and minimize the side effects. We employed a mesoporous silica-templating to prepare uniform and monodisperse silicates (Figure [14](#F14){ref-type="fig"}A,B) [@B58]. By simply adjusting the metal dopants, silicate nanoscintillators with a controlled size and X-ray excited optical luminescence (450-900 nm) were synthesized. They were than modified with rose bengal (RB), a photosensitizer with four iodine atoms and a drug commonly used in clinical trials (Clinical Trials ID NCT02288897). Typically, silicates with Zn- and Mn-dopants (ZSM) emitted XEOL that matched well with the absorption of RB (Figure [14](#F14){ref-type="fig"}C). Under a low-dose of X-ray irradiation (0.75 Gy), the silicate nanosensitizers achieved excellent reactive oxygen species (ROS) generation and significant inhibitory effects on tumor progression were observed, while minimally affecting normal tissues (Figure [14](#F14){ref-type="fig"}A). X-ray energy can be deposited in the nanoscintillators to generate the PDT process, inducing cell death (Figure [14](#F14){ref-type="fig"}D,E). The addition of iodine to radiosensitizers can be utilized to enhance the RT efficiency by increasing both the yield and the effects of •OH (Figure [14](#F14){ref-type="fig"}F), thereby enhancing the efficacy of X-PDT (Figure [14](#F14){ref-type="fig"}G).

Hafnium oxide has been clinically used to enhance RT in both Europe and the US (<https://www.nanobiotix.com/_en/news>). In 2004, the Lin group found that heavy metal clusters and luminescent organic bridging ligands could be synergistically assembled in metal-organic frameworks (MOFs) to achieve efficient X-ray scintillation (Figure [15](#F15){ref-type="fig"}A) [@B59]. The MOFs employed high-Z metal clusters M~6~(μ~3~-O)~4~(μ~3~-OH)~4~(carboxylate)~12~ (M = Hf or Zr) as connecting nodes and an anthracene-based emitter as the bridging ligand. Upon irradiation of X-rays (20-200 keV), the MOFs emitted XEOL in the visible light region (Figure [15](#F15){ref-type="fig"}B). In 2017, the Lin group reported metal-organic layers (MOLs) that were built from \[Hf~6~O~4~(OH)~4~(HCO~2~)~6~\] and Ir\[bpy(ppy)~2~\]^+^ or \[Ru(bpy)~3~\]^2+^ ligands (Figure [15](#F15){ref-type="fig"}C) [@B9]. Both ligands were efficient photosensitizers, with high quantum yields of ^1^O~2~. The Ir-based MOLs generated ^1^O~2~ more efficiently and induced more cancer cell death than the Ru-based MOLs upon X-ray irradiation. In addition, Hf-MOLs had a much higher ^1^O~2~ generation efficiency than Zr-MOLs, which could be attributed to the better absorption of X-ray energy by the heavier Hf atom compared to the Zr atom. The *in vitro* and *in vivo* studies indicated that cancer cells were effectively killed and tumor regression was observed on CT26 and MC38 tumor models after an intratumoral injection of Hf-MOLs followed by X-ray irradiation (Figure [15](#F15){ref-type="fig"}D-G). These discoveries confirmed that MOFs containing heavy metal secondary building units displayed superb RT efficiency in these tumor models. Furthermore, the Lin group optimized the structural and compositional tunability of MOFs based on electron-dense Hf~12~ or Hf~6~ clusters and strongly photosensitizing Ir(DBB)\[dF(CF~3~)ppy\]^2+^ bridging ligands to improve the efficacy of X-PDT [@B60]. Upon X-ray irradiation, the Hf~12~ or Hf~6~ clusters efficiently absorbed X-rays to enhance RT by producing •OH and induced the PDT process through the excitation of Ir(bpy)\[dF(CF~3~)ppy\]^2+^ derived ligands to generate ^1^O~2~ and superoxide anions. *In vitro* and *in vivo* experiments showed that Hf~12~-Ir and Hf~6~-Ir MOFs promoted effective cell death by combining RT and PDT, resulting in significant tumor regression at low X-ray doses (0.5 × 5 Gy).

Selective delivery of photosensitizers to the mitochondria of cancer cells can enhance the therapeutic efficacy. To achieve this, the Lin group prepared Hf-DBB-Ru (DBB-Ru = bis(2,2\'-bipyridine)(5,5\'-di(4-benzoato)-2,2\'-bipyridine)ruthenium(II) chloride) as a mitochondria-targeted MOF for X-PDT [@B61]. By incorporating cationic Ru-based photosensitizers, the cationic MOFs were successfully constructed. The cationic MOFs exhibited strong mitochondria-targeting properties. Upon X-ray irradiation, Hf-DBB-Ru efficiently generated •OH from the Hf~6~ clusters and ^1^O~2~ from the DBB-Ru photosensitizers to produce an X-PDT effect. *In vivo* studies demonstrated that the mitochondria-targeted X-PDT depolarized the mitochondrial membrane to initiate apoptosis of cancer cells, leading to significant regression of colorectal tumors in mouse models.

To advance this technology, it is critical to demonstrate that nanoparticles can be injected systemically and, following external X-ray irradiation, activate X-PDT *in situ* to kill cancer cells in deep tissues. For this purpose, it is paramount to investigate the treatment in a clinically relevant model, not a subcutaneous tumor model. To simulate a clinically relevant model, deep-seated tumors were mimicked by putting a layer of pork (1-2 cm thickness) between a subcutaneous lung tumor model and an X-ray generator, and the efficacy of X-PDT was evaluated [@B16]. After injecting SAO:Eu\@mSiO~2~ intratumorally and irradiating with X-rays, tumor growth was slowed in all the treatment groups, while tumors in the control group grew very rapidly (Figure [16](#F16){ref-type="fig"}A). The results suggested that tissue thickness had little effect on the efficacy of X-PDT. Encouraged by the excellent tumor growth inhibition, the X-PDT efficacy was then investigated by injecting the mixture of MC540-SAO:Eu\@mSiO~2~ nanosensitizers and firefly luciferase expressing H1299 cells into the thorax of mice. Radiation (5 Gy) was applied to the tumor inoculation sites, and the tumor growth was then monitored *in vivo* by bioluminescence imaging (BLI). In X-PDT treated animals, the BLI signals were significantly suppressed, and in other groups, the BLI signals were detected in the lung areas on day 7, with the signals increasing further afterwards (Figure [16](#F16){ref-type="fig"}B,C). *Ex vivo* imaging confirmed the efficacy of X-PDT induced tumor suppression, finding strong residual signals in the lungs of control animals but close-to-background signals from the X-PDT group (Figure [16](#F16){ref-type="fig"}D,E).

It is critical to find a way to track the particle migration *in vivo* and navigate external irradiation to tumor areas. These questions have not yet been addressed and the considerations are different from *in vitro* studies with regard to materials, nanoparticle engineering, experimental designs, and toxicity. For the limited number of *in vivo* studies described so far, nanoparticles were all injected directly into tumors. To this end, one question which needed to be answered was how to navigate the treatment of tumors with accuracy using external irradiation. This issue was resolved by using LiGa~5~O~8~:Cr (LGO:Cr)-based nanoparticles as transducers for imaging-guided *in vivo* X-PDT (Figure [17](#F17){ref-type="fig"}A) [@B62]. LGO:Cr emitted persistent, near-infrared X-ray luminescence (Figure [17](#F17){ref-type="fig"}B), which was then coated with a layer of mesoporous silica to match the photosensitizers (2,3-naphthalocyanine (NC)) and modify the surface (Figure [17](#F17){ref-type="fig"}C). Specifically, after PEGylation and conjugation with the targeting agent cetuximab (CTX), the LGO:Cr\@mSiO~2~-PEG-CTX nanosensitizers were able to accumulate efficiently in the H1299 orthotopic non-small cell lung cancer tumors implanted into the lung after intravenous injection and were confirmed by monitoring the X-ray luminescence from LGO:Cr (Figure [17](#F17){ref-type="fig"}D). The tumor selectivity was further improved by navigating the X-ray irradiation to the tumor areas with imaging guidance. Guided by the imaging, external irradiation was applied, leading to efficient tumor suppression while minimally affecting normal tissue (Figure [17](#F17){ref-type="fig"}E). At the end of the therapy, the X-PDT group showed lower BLI signals than that of control groups, further confirming the therapeutic efficacy (Figure [17](#F17){ref-type="fig"}F).

As a traditional clinical therapy methodology, RT has become a very important strategy for cancer management. In recent years, immunotherapy has been of great interest to researchers, clinicians, and pharmaceutical companies. New strategies for the combination of traditional RT and emerging immunotherapy for cancer treatment have been developed in parallel. The Lin group have recently confirmed a synergistic effect when combining nano-MOFs with cancer immunotherapy [@B7]. In that research, the Lin group bridged Hf/Zr-MOFs-enabled X-PDT and checkpoint blockade immunotherapy to develop radio-enhancers for X-ray radiotherapy for both local and systemic tumor elimination (Figure [18](#F18){ref-type="fig"}A). In all radioresistant head and neck squamous cell carcinoma (SQ20B), glioblastoma (U87MG), prostate cancer (PC-3), and colorectal cancer (CT26) tumor models, intratumoral delivery of 5,15-di(*p*-benzoato)porphyrin (DBP)-Hf and 5,10,15,20-tetra(*p*-benzoato)porphyrin (TBP)-Hf nano-MOFs caused efficient tumor regression at low doses of X-ray irradiation. When loaded with an inhibitor of the immune checkpoint molecule indoleamine 2,3-dioxygenase (IDOi), consistent abscopal responses were observed in all treatment of CT26 and TUBO tumor models with low-doses of X-rays (Figure [18](#F18){ref-type="fig"}B). The treatment not only minimized the side effects of local RT, but also caused systemic immunity to efficiently inhibit tumor growth. By combining the advantages of local RT and systemic tumor rejection *via* synergistic X-ray-induced *in situ* vaccination and indoleamine 2,3-dioxygenase inhibition, MOF-based nanoplatforms may overcome some of the limitations of RT and checkpoint blockades in cancer treatment. Based on this radio-immuno metal-organic (RiMO) technology, a Phase 1 study of RiMO-301 in patients with advanced tumors has been initiated (<https://clinicaltrials.gov/ct2/show/NCT03444714>).

Future perspectives
===================

Although X-PDT has demonstrated good efficacy and benefits, the development of this new therapeutic method is still in its infancy. As discussed above, X-PDT treatment is essentially a combination therapy of PDT and ionizing irradiation. However, how to deal with the interplay between the two methods and how we can further improve this synergy by tuning irradiation parameters and/or changing a transducer\'s targeting ability remain a major challenge.

By now, only two simulations have been proposed. These simulations were the photon cross section model and the electron cross section model. Both simulations used fluorides as a case study and concluded that an irradiation level in excess of 60 Gy was required to achieve enough ^1^O~2~ per cell to deliver a killing dose. *In vivo* investigations on xenograft tumor models (both of subcutaneous and orthotopic tumors) demonstrated that low-dosages of X-rays (\<5 Gy) were sufficient to inhibit or eradicate tumor growth by both intratumoral injection and systemic administration. These *in vivo* experimental results were inconsistent with the conclusions from the simulations. So, perhaps, there are additional mechanisms besides the PDT and RT processes at work. More investigation into the contribution of X-ray luminescence and fluorescence on cell lethality should be performed. UV and other ionizing irradiation was generated during the scintillation process. Deep-UV light alone can be harnessed to damage cells and cancerous tissues. In sum, it is fair to admit that X-PDT is intrinsically a complicated process and cell death is the result of multiple factors. These understudied factors could account for the discrepancy between the theoretical models and experimental studies. So, the mechanism by which X-PDT induces cell death should be carefully investigated based on the experimental results.

It is important to note that exploiting methods to improve the energy conversion and safety profiles of scintillators is key to X-PDT. There are several aspects to consider when engineering scintillators including: (1) constructing scintillators that have a large X-ray absorption cross-section, high conversion efficiency of X-rays to visible photons, and optimized spatial positioning of the molecular entities involved; (2) reducing the overall size of the transducers, which must be balanced against the loss of energy conversion efficiency. It is noteworthy that many of the reported transducers in X-PDT have a relatively large size, which is suboptimal for tumor targeting; and (3) striking a balance between short-term stability and fast biodegradation of scintillators. The high XEOL efficiency of transducers under low-dose X-rays should be initially considered. Moreover, the transducers with a controlled size distribution in the range of 50-200 nm should exhibit prolonged blood circulation, a relatively low rate of uptake by the reticuloendothelial or mononuclear phagocyte systems, and an increased rate of tumoral uptake based on enhanced permeability and retention effects. Additionally, the modification of stealth components (*e.g.*, polyethylene glycol, zwitterionic molecules) onto the surface of nanoparticles can reduce nonspecific protein corona formation *in vivo*. Most importantly, the nanosensitizers should be non-toxic and easily metabolized with low long-term toxicity. Most of the excellent scintillator candidates, such as aluminate and all-inorganic perovskites, are hydrolytic in nature, and could quickly break up into their constituent ions when exposed to water. One solution to this problem is to use coating materials to decorate hydrolytic scintillator cores so as to enhance their physiological stability in media. The materials/ coating strategies should be exploited to modulate the stability and degradation of scintillators *in vivo*. Moreover, the number of photosensitizers loaded in scintillators and the distance between them determine the energy transfer efficiency from scintillators to photosensitizers. Therefore, a covalent conjugation strategy for combining photosensitizers and scintillators with controllable intra-component distance may be more applicable than a physical loading method. So far, there have been few studies that systematically examine these on X-PDT efficacy.

So far, X-PDT has been demonstrated mostly *in vitro* or with subcutaneous tumor models *in vivo*. It is expected that many clinically relevant tumor models, especially the deeply-located tumors, could be cured by this methodology. Besides, most of the *in vivo* studies are conducted by intratumoral injection of nanosensitizers, which is not conducive to the non-invasive clinical treatment of deep orthotopic cancer. This would call for great specificity in the uptake of the X-PDT nanoplatforms in these cancer cells. It could be completed by introducing *in vivo* active targeting effects through conjugation with various cancer targeting agents, such as folic acid, RGD (for integrin α~v~β~3~), cetuximab and panitumumab (for epidermal growth factor receptor), herceptin (for human epidermal growth factor receptor 2), bevacizumab (for vascular endothelial growth factor) and so on. For example, mitochondria-targeting agents achieved high accumulation in mitochondria, and X-ray irradiation produced ROS which induced significantly mitochondrial collapse and cellular apoptosis than X-ray alone. So, the methodology of altering the energy deposition profile in cells may contribute to the cell killing mechanism of X-PDT.

The low-dose irradiation activated X-PDT holds the potential for clinical translation as an alternative to ionizing irradiation therapy. It is important to compare the two methods in a clinical environment to assess the benefits and drawbacks of X-PDT with regards to therapeutic efficacy and side effects. It is meaningful to evaluate the capacity of X-PDT to treat radiation-refractory tumors. In RT, pre-treatment functional imaging (*e.g.*, positron emission tomography) is often performed to stage tumors and guide irradiation planning. However, functional imaging is not permitted in an irradiation room, and a change in the status of the patient from pre-scans may occur, leading to setup errors. Many scintillators contain high-Z elements, making them visible under on-board CT. It is thus possible to use these scintillators to not only regulate PDT, but also to guide the irradiation to minimize damage to normal tissue. These possibilities should also be investigated to facilitate clinical translation of X-PDT.

Conclusions
===========

There have been dramatic developments in the feasibility of X-PDT as a novel cancer treatment methodology over the past decades. X-PDT has shown promising therapeutic effects by combining PDT and RT methods to treat deep-seated tumors. In this review, we have attempted to provide an overview of the research developments in X-PDT strategy, including the concept, the related design parameters, the combined therapy mechanism, the biomedical applications, and the concluding prospects. As a synergistic PDT and RT procedure, X-ray-activated PDT overcomes the limitation of light penetration depth in traditional light-activated PDT, and less irradiation is needed in X-PDT for tumor ablation than in traditional RT. However, the real biomedical applications of X-PDT are still in the early development stage. We hope that this review will provide a timely overview of the current situation in this field and point to new positive directions in the battle against cancer.
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![Timeline of the milestone research studies on X-PDT.](thnov10p1296g001){#F1}

![Schematic illustration showing the mechanism of X-PDT.](thnov10p1296g002){#F2}

![Investigation of the cell-killing mechanism of X-PDT. (A) Apoptosis and necrosis assay performed 24 h after X-PDT. (B) Lipid peroxidation assay. (C) Comet assay. (D) Western blot assay. H1299, a radioresistant non-small cell lung cancer cell line was employed. Adapted with permission from Ref [@B16]. Copyright 2016 Ivyspring Publisher.](thnov10p1296g003){#F3}

![Theory simulation of a scintillator\'s effect on X-PDT. (A) Light yield of scintillators and cathode ray tube phosphors. Adapted with permission from Ref [@B21]. Copyright 2002 Elsevier. (B) Energy deposited in matter (E~matter~) for one *γ* photon interaction in a tumor of volume *V*~tum~ loaded with 10 nm diameter nanoparticles, with an occupation ratio of 7 × 10*^-^*^3^. The absorption of the photons (Abs.) is calculated for the two considered energies (100 keV and 500 keV). *η*~nano~ quantifies the fraction of energy that is deposited in the nanoparticles themselves. Adapted with permission from Ref [@B22]. Copyright 2015 Royal Society of Chemistry.](thnov10p1296g004){#F4}

![Optimization of both scintillators and photosensitizers to achieve efficient and enhanced X-PDT.](thnov10p1296g005){#F5}

![Fluorides and oxides for use with of X-PDT. (A) Quenching of ADPA with X-ray irradiation. Adapted with permission from Ref [@B33]. Copyright 2008 American Institute of Physics. (B) Scheme of LaF~3~:Tb-RB-mediated X-PDT. (C) Decrease in the emission of DPBF treated with LaF~3~:Tb-RB and X-rays. Adapted with permission from Ref [@B34]. Copyright 2015 American Chemical Society. (D) Synthesis of porphyrin-Tb~2~O~3~\@SiO~2~. (E) XEOL of Tb~2~O~3~\@SiO~2~. (F) ^1^O~2~ generation of porphyrin-grafted Tb~2~O~3~\@SiO~2~ under X-ray irradiation. Adapted with permission from Ref [@B36]. Copyright 2013 American Chemical Society.](thnov10p1296g006){#F6}

![(A) Schematic representation of the Hyp-GdEuC1~2~ micelles and the respective structures of the amphiphilic GdLnC1~2~ complex and the Hyp. (B) Overlay between the XEOL of EuCl~3~ (black line) and the absorption spectrum of Hyp (gray line). (C) ^1^O~2~ production of Hyp-GdEuC12 micelles as indicated by the abundance of 1-pyrenecarboxaldehyde, measured by mass spectrometry (∆: non-irradiated, □: irradiated). Adapted with permission from Ref [@B37]. Copyright 2015 Springer. (D) Crystallographic structure of (n-Bu~4~N)~2~\[Mo~6~I~8~(OOC-1-adamantane)~6~\] (blue, molybdenum; magenta, iodine; red, oxygen; black, carbon; hydrogen atoms are omitted for clarity). (E) Scheme of (n-Bu~4~N)~2~\[Mo~6~I~8~(OOC-1-adamantane)~6~\] cluster-mediated X-PDT. Adapted with permission from Ref [@B39]. Copyright 2015 American Chemical Society.](thnov10p1296g007){#F7}

![(A) Cellular metabolic activities using Gd~2~O~2~S:Tb particles as transducers under X-ray irradiation. Adapted with permission from Ref [@B41]. Copyright 2011 IOS Press. (B) Synthesis of TAT- and PsTAT-Y~2~O~3~ scintillators. (C) Percentage of cancer cells remaining after the treatment with TAT-Y~2~O~3~ or PsTAT-Y~2~O~3~ under X-ray irradiation. Adapted with permission from Ref [@B42]. Copyright 2011 American Chemical Society. (D) The X-ray excited luminescence and afterglow spectra of ZnS:Cu,Co scintillators overlapped with the absorption of TBrRh123. (E) Afterglow decay of ZnS:Cu,Co scintillators. (F) Viabilities of PC3 cells treated with ZnS:Cu,Co-TBrRh123 before and after X-ray irradiation. Adapted with permission from Ref [@B45]. Copyright 2014 American Institute of Physics. (G) Scheme illustrating the ^1^O~2~ production from porphyrin-SiC/SiOx nanowires (NWs) excited by X-rays. (H) Surviving fraction of cells treated only with porphyrin-SiC/SiOx NWs (50 μg·mL^-1^), only with radiation (2 Gy), or a combination of porphyrin-SiC/SiOx NWs and X-rays (2 Gy). Each letter indicates a different level of significance (p\<0.05). (I) ATP levels in A549 cells treated with porphyrin-SiC/SiOx and X-rays. Adapted with permission from Ref [@B46]. Copyright 2015 Nature Publishing Group.](thnov10p1296g008){#F8}

![(A) Schematic illustration of the synthetic route to ZnO coated LiYF~4~:Ce (SZNP). (B) The mechanism of SZNP-mediated X-PDT. (C) Viabilities of normoxic and hypoxic HeLa cells treated with SZNPs for 24 h under X-ray radiation (0, 2, 4, 6 Gy). (D) *In vivo* evaluation of SZNPs-mediated synchronous RT and PDT. Adapted with permission from Ref [@B49]. Copyright 2014 Wiley-VCH.](thnov10p1296g009){#F9}

![(A) Schematic illustration of the structure of M-SAO\@SiO~2~ and the working mechanism of SAO-based X-PDT. (B) The XEOL of SAO (red) and the absorption of MC540 (black). (C) Viabilities of U87MG cells with different treatments. (D) Tumor growth curves of mice intratumorally injected with M-SAO\@SiO~2~, SAO\@SiO~2~, and PBS, followed by X-ray irradiation. M-SAO\@SiO~2~: Nanosensitizers consisted of a core made of SrAl~2~O~4~:Eu (SAO) and a silica coating loaded with merocyanine 540 (MC540), SAO\@SiO~2~: Silica-coated SrAl~2~O~4~:Eu. Adapted with permission from Ref [@B8]. Copyright 2015 American Chemical Society.](thnov10p1296g010){#F10}

![(A) Scheme of the synthesis of ZGO:Cr/W-ZnPcS4 and its performance in the subcutaneous tumor model. (B) X-ray excited persistent luminescence spectra of ZGO:Cr/W and ZGO:Cr nanoparticles. (C) Tumor growth curves for different groups of tumor-bearing mice after various treatments. Adapted with permission from Ref [@B51]. Copyright 2018 WILEY-VCH.](thnov10p1296g011){#F11}

![(A) Schematic illustrations of the process of the preparation of silicate nanosensitizers (RGD-ZSM-RB) and of the mechanism of RGD-ZSM-RB mediated X-PDT. (B) The XEOL spectra of GCs and AIE-GCs. (C) The absorption spectra of ABDA (^1^O~2~-detection probe) in different solutions with or without X-ray irradiation (50 kV, 70 μA). (D) DNA damage (dashed circle) assessed by single cell electrophoresis assays (Scale bar, 10 µm). (E) Cell proliferation capacity measured by clonogenic assays. Tumor growth curves of (F) U87MG, (G) HepG2 and (H) PC3 tumor-bearing mice after different treatments. Adapted with permission from Ref [@B56]. Copyright 2019 WILEY-VCH.](thnov10p1296g012){#F12}

![(A) Schematic of the structure of NSC\@mSiO2-SNO/ICG NPs and their passive accumulation in tumors via the EPR effect. (B) X-ray radiation on this system would trigger multiple tumoricidal responses by: (I) increasing dose deposition to accelerate radiolysis, (II) producing cytotoxic ROS by activating ICG based on the scintillation effect of NSC, and (III) releasing high levels of NO due to radiation fracture of S-N bonds. Adapted with permission from Ref [@B57]. Copyright 2018 Ivyspring Publisher.](thnov10p1296g013){#F13}

![(A) Schematic illustrations of the process of the preparation of silicate nanosensitizers (RGD-ZSM-RB) and of the mechanism of RGD-ZSM-RB mediated X-PDT. (B) TEM image of silicate nanosensitizers (Scale bar, 50 nm). (C) The overlap of the XEOL spectrum of ZSM and the absorption spectrum of RB. (D) Fluorescence images of calcein AM (green fluorescence for live cells) and PI (red fluorescence for dead cells) co-stained U87MG cells with different treatments (Scale bar, 100 µm). (E) Lipid damage assessment measured by lipid peroxidation assays. (F) DNA damage (dashed circle) assessed by single cell electrophoresis assays (Scale bar, 25 µm). (G) Cell reproductive capacity measured by clonogenic assays taken 10 d after RT or X-PDT. Adapted with permission from Ref [@B58]. Copyright 2019 WILEY-VCH.](thnov10p1296g014){#F14}

![(A) Scheme showing X-ray induced generation of fast photoelectrons from heavy metals followed by scintillation of the anthracene-based linkers in the visible spectrum. (B) Optical spectra of Hf-MOFs and Zr-MOFs induced by X-ray irradiation at a dose of 6 Gy·min^-1^. Adapted with permission from Ref [@B59]. Copyright 2014 American Chemical Society. (C) Schematic illustration of the synthesis of Hf-based MOLs and MOL-enabled X-PDT to generate ^1^O~2~. Viabilities of (D) CT26 cells and (E) MC38 cells with different treatments. (F) CT26 and (G) MC38 tumor growth curves after different treatments. Adapted with permission from Ref [@B9]. Copyright 2017 Wiley-VCH.](thnov10p1296g015){#F15}

![(A) X-PDT efficacy to treat subcutaneously implanted tumors from above thick tissue. (B) Representative bioluminescence images of mice that were injected with a SAO:Eu nanosensitizers and firefly luciferase expressing H1299 cell mixture to the thorax and treated by X-PDT, RT, and Controls. (C) Tumor growth measured by monitoring the bioluminescence imaging (BLI) signal changes at different time points. (D) *Ex vivo* bioluminescence images taken immediately after tissue dissection. The organs were organized in the following order: left column (from top to bottom): skin, liver, spleen and intestine; right column (from top to bottom): kidneys, heart, lung, brain and muscle. (E) BLI signals from the lungs based on the ROI analyses on (B). Adapted with permission from Ref [@B16]. Copyright 2016 Ivyspring Publisher.](thnov10p1296g016){#F16}

![(A) Schematic illustration for the design and mechanism of LGO:Cr\@mSiO~2~ mediated X-PDT. (B) The absorption spectrum of 2,3-naphthalocyanine (NC) (black) and the XEOL spectrum of LGO:Cr (red). (C) TEM image of LGO:Cr\@mSiO~2~. (D) *In vivo* imaging based on X-ray excited persistent luminescence signals and assessed in H1299 lung tumor models. (E) Tumor growth assessed by monitoring BLI signal changes at different time points. (F) Representative bioluminescence imaging for the three treatment groups taken on day 7. Adapted with permission from Ref [@B62]. Copyright 2017 Royal Society of Chemistry.](thnov10p1296g017){#F17}

![(A) Scheme of nano-MOF enabled synergistic X-RDT and immunotherapy using extremely low doses of X-rays. (B) Growth curves of CT26 and TUBO tumor-bearing mice intravenously administered with PBS, DBP-Hf, IDOi\@DBP-Hf, or DBP-Hf + IDOi, with or without X-ray irradiation. Adapted with permission from Ref [@B7]. Copyright 2018 Nature Publishing Group.](thnov10p1296g018){#F18}

###### 

Investigations of X-PDT.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Major milestones                          Publication Year               Dose                                          Transducer                                   Size /nm                                  Photosensitizers            Attachment strategy         Exp. subject      Ref.
  ----------------------------------------- ------------------------------ --------------------------------------------- -------------------------------------------- ----------------------------------------- --------------------------- --------------------------- ----------------- --------
  Concept proposed                          2006                           N/A                                           LaF~3~:Ce, LuF~3~:Ce, CaF~2~:Mn,\            N/A                                       N/A                         N/A                         concept           [@B10]
                                                                                                                         CaF~2~:Eu, BaFBr:Eu, BaFBr:Mn, CaPO~4~:Mn\                                                                                                                       
                                                                                                                         ZnO, ZnS, TiO~2~                                                                                                                                                 

                                                                                                                                                                                                                                                                                          

  Simulation                                2009                           0.1-100 Gy                                    LaF~3~:Ce, LuF~3~:Ce, CaF~2~:Mn,\            N/A                                       photofrin,\                 N/A                         in solution       [@B19]
                                                                                                                         CaF~2~:Eu, BaFBr:Eu, BaFBr:Mn, CaPO~4~:Mn\                                             fullerenes, TiO~2~                                                        
                                                                                                                         ZnO, ZnS, TiO~2~                                                                                                                                                 

  2015                                      100/500 keV                    Gd~2~O~3~, Gd~2~O~2~S, Lu~2~O~3~, CdSe, InP   100                                          N/A                                       N/A                         in solution                 [@B22]            

                                                                                                                                                                                                                                                                                          

  Mechanistic study                         2016                           5 Gy                                          SrAl~2~O~4~:Eu\@mSiO~2~                      73.5                                      MC540                       pore loading                animal (it)       [@B16]

                                                                                                                                                                                                                                                                                          

  Solution evaluation                       2008                           250 kV, 0.44 Gy·min^-1^                       LaF~3~:Tb                                    15                                        MTCP                        covalent binding            in solution       [@B33]

  2015                                      75 kV, 20 mA                   LaF~3~:Tb                                     39                                           rose bengal                               covalent binding            in solution                 [@B34]            

  2015                                      75 kV, 20 mA                   LaF~3~:Tb\                                    40                                           rose bengal                               covalent binding            in solution                 [@B35]            
                                                                           \@SiO~2~                                                                                                                                                                                                       

  2013                                      44 kV, 40 mA, 14.6 Gy          Tb~2~O~3~                                     3                                            porphyrin                                 covalent binding            in solution                 [@B36]            

  2015                                      400 mA, 10^15^ photons·s^-1^   GdEuC12 micelles                              4.6                                          hypericin                                 physical loading            in solution                 [@B37]            

  2016                                      40 kV, 15 mA                   \[M~6~L^i^~8~L^a^~6~\]^n^ complexes           N/A                                          self                                      complex                     in solution                 [@B39]            

                                                                                                                                                                                                                                                                                          

  *In vitro* evaluation                     2007                           1-10 Gy                                       TiO~2~, ZnS:Ag, CeF~3~, CdTe and CdSe        N/A                                       self                        N/A                         HeLa cells        [@B40]

  2011                                      120 kVp, 20 mA                 Gd~2~O~2~S:Tb                                 20 μm                                        photofrin II                              co-location                 glioblastoma cells          [@B41]            

  2011                                      2 Gy                           Y~2~O~3~                                      12                                           psoralen                                  physical attachment         PC3 cells                   [@B42]            

  2014                                      120 kV, 2 Gy                   ZnS:Cu,Co                                     4                                            TBrRh123                                  covalent binding            PC3 cells                   [@B45]            

  2015                                      6 MV, 2 Gy                     SiC/SiO~x~ nanowires                          20                                           H~2~TPACPP                                covalent binding            A549 cells                  [@B46]            

                                                                                                                                                                                                                                                                                          

  *In vivo* evaluation (intratumor)         2015                           220 keV, 8 Gy                                 LiYF~4~:Ce                                   40                                        ZnO                         coating                     animal (it)       [@B49]

  2018                                      80 kV, 4 Gy                    LiLuF~4~:Ce                                   30                                           Ag~3~PO~4~-Pt(IV)                         coordination                animal (it)                 [@B17]            

  2017                                      120 kV, 20 mA                  \[Hf~6~O~4~(OH)~4~(HCO~2~)~6~\] SBUs          500                                          Ir\[bpy ppy)~2~\]^+^ \[Ru(bpy)~3~\]^2+^   post-synthetic metalation   animal (it)                 [@B9]             

  2018                                      5 × 0.5 Gy                     Hf~6~ SBUs, Hf~12~ SBUs                       295.3, 91.3                                  Ir(DBB)\[dF(CF~3~)ppy\]~2~^+^             post-synthetic metalation   animal (it)                 [@B60]            

  2015                                      50 kV, 70 μA, 0.5 Gy           SrAl~2~O~4~:Eu                                150                                          MC540                                     pore loading                animal (it)                 [@B8]             

                                                                                                                                                                                                                                                                                          

  *In vivo* evaluation (intravenous)        2018                           50 kV, 60 µA, 0.18 Gy                         ZnGa~2~O~4~:Cr/W                             15                                        ZnPcS~4~                    pore loading                animal (iv)       [@B51]

  2018                                      250 kVp, 15 mA                 Hf-DBB-Ru                                     98                                           DBB-Ru                                    coordination                animal (iv)                 [@B61]            

  2019                                      50 kV, 70 μA, 6 Gy             Gd~2~(WO~4~)~3~:Tb                            50                                           MC540                                     physical attachment         animal (iv)                 [@B52]            

  2019                                      50 kV, 70 μA, 1 Gy             AIE-Au                                        68.2                                         rose bengal                               bioconjugation              animal (iv)                 [@B56]            

  2019                                      50 kV, 70 μA, 1 Gy             Zn~2~SiO~4~:Mn                                30-120                                       rose bengal                               bioconjugation              animal (iv)                 [@B58]            

                                                                                                                                                                                                                                                                                          

  *In vivo* evaluation (orthotopic tumor)   2017                           50 kV, 70 μA, 5 Gy                            LiGa~5~O~8~:Cr                               100                                       NC                          pore loading                animal (iv)       [@B62]

                                                                                                                                                                                                                                                                                          

  Combined therapy                          2018                           0.5 Gy·fraction^-1^                           DBP-Hf, TBP-Hf nMOFs                         72                                        self                        post-synthetic metalation   animal (it, iv)   [@B7]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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